Development and Validation of a Scale of Propensity for Change in Chronic Disease Prevention
NCT07765797
Arterial Occlusive Diseases, Arteriosclerosis
Toulouse, Oui, France
View Trial DetailsNCT Number: NCT07772466
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease primarily affecting the peripheral joints, yet its extra-articular burden particularly on the cardiovascular (CV) system has emerged as its most consequential long-term complication . Cardiovascular disease (CVD) accounts for 40% of all deaths in RA patients, making it the leading cause of mortality .This excess CV risk is estimated to be 1.5 to 2 times higher than in the general population .The overall CV risk conferred by RA has been linked in magnitude to that of diabetes mellitus, underscoring RA as an independent cardiovascular risk factor formally recognised in the 2021 European Society of Cardiology Guidelines on CVD prevention .
In this context, the non-invasive detection of preclinical atherosclerosis before the onset of clinical CV events has become clinical priority. Carotid intima-media thickness (CIMT), measured by high-resolution B-mode ultrasonography, is a well-validated surrogate marker of early structural arterial wall changes that independently predicts future myocardial infarction and stroke .Multiple studies have documented significantly elevated CIMT in RA patients compared with age- and sex-matched controls; studies found higher CIMT values across all age groups in RA, with values increasing in proportion to disease severity as assessed by the Disease Activity Score in 28 joints .
The atherogenic index of plasma (AIP) defined as the base-10 logarithm of the triglyceride-to-HDL-cholesterol ratio has emerged as a calculated composite biomarker reflecting lipoprotein particle atherogenicity, particularly the preponderance of small, dense LDL particles .A high AIP (>0.21) has been independently associated with major adverse cardiovascular events beyond the predictive capacity of conventional lipid panels .
Trial opening soon.
Get Notified18 year–50 year
All sexes
Observational
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for cases (Rheumatoid Arthritis patients)
For Controls (Healthy Subjects):
Exclusion criteria
Time frame: • Disease duration of ≤6 months from the onset of symptoms
Assiut University
Other
Atherogenic Index of Plasma and Carotid Intima-media Thickness as Predictors of Preclinical Atherosclerosis in Early Rheumatoid Arthritis Patients Younger Than 50 Years of Age
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07765797
Arterial Occlusive Diseases, Arteriosclerosis
Toulouse, Oui, France
View Trial DetailsNCT07556887
Arterial Occlusive Diseases, Arteriosclerosis
Arnhem, Gelderland, Netherlands
View Trial DetailsNCT07493603
Arterial Occlusive Diseases, Arteriosclerosis
Huzhou, Zhejiang, China
View Trial DetailsNCT07460960
Androgen Profile, Arterial Occlusive Diseases
Moscow, Russia
View Trial Details